Topical Application of Dehydroxymethylepoxyquinomicin Improves Allergic Inflammation via NF-κB Inhibition

The study demonstrated that dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-κB inhibitor, effectively reduced allergic inflammation in atopic dermatitis (AD) model mice. DHMEQ suppressed NF-κB activity, reduced inflammatory cytokine expression, and inhibited Langerhans cell migration. Topical application of DHMEQ significantly improved the severity of AD-like skin lesions, showing efficacy comparable to tacrolimus and betamethasone. These findings suggested that DHMEQ could be a promising therapeutic option for AD, especially for cases unresponsive to conventional treatments.